BioCentury
ARTICLE | Politics, Policy & Law

Biotech CEOs respond to Sanders attack: science, not politics, will defeat the pandemic

BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.

Steve Usdin, Washington Editor
March 16, 2020 3:17 AM UTC
Updated on Mar 24, 2020 at 10:55 PM UTC


Access this Article

BCIQ Company Profiles

Acorda Therapeutics Inc.

Ovid Therapeutics Inc.

Alnylam Pharmaceuticals Inc.

Arch Venture Partners

Biotechnology Innovation Organization

Next in Daily Edition for March 16, 2020

articlePolitics, Policy & LawMar 16, 2020

Biotech CEOs respond to Sanders attack: science, not politics, will defeat the pandemic

BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.

articleProduct DevelopmentMar 17, 2020

Phase II data bring Blueprint closer to major market expansion for Ayvakit

articleProduct DevelopmentMar 16, 2020

COVID-19 Roundup: Trial starts for Moderna, Sanofi-Regeneron and BioNTech; plus Thermo Fisher, Roche and VIB

BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.

articleProduct DevelopmentMar 17, 2020

Bumpy ride for debut of Verily’s COVID-19 screening platform

articleProduct DevelopmentMar 16, 2020

Teva, Celltrion launch fourth U.S. Herceptin biosimilar at modest discount

articleProduct DevelopmentMar 17, 2020

March 16 Quick Takes: FDA raises efficacy questions for DBV allergy therapy; plus Novo, Provention, UCB, Pfizer-EMD Serono, Zai, AcelRx-Tetraphase, Medivir-Tan

articlePolitics, Policy & LawMar 16, 2020

Grassley-Wyden drug price bill attacks rebates, includes inflation caps

articleManagement TracksMar 16, 2020

CureVac CEO Hoerr takes leave of absence; German biotech rejects reports of U.S. approach for COVID-19 vaccine

BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.